Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 15;155(10):1705-1713.
doi: 10.1002/ijc.35067. Epub 2024 Jun 27.

The m6A-independent role of epitranscriptomic factors in cancer

Guglielmo Bove  1 , Marco Crepaldi  1 , Sajid Amin  1 , Wouter Leonard Megchelenbrink  1   2 , Angela Nebbioso  1   3 , Vincenzo Carafa  1   4 , Lucia Altucci  1   2   4   5 , Nunzio Del Gaudio  1
Affiliations
Review

The m6A-independent role of epitranscriptomic factors in cancer

Guglielmo Bove et al. Int J Cancer. .

Abstract

Protein function alteration and protein mislocalization are cancer hallmarks that drive oncogenesis. N6-methyladenosine (m6A) deposition mediated by METTL3, METTL16, and METTL5 together with the contribution of additional subunits of the m6A system, has shown a dramatic impact on cancer development. However, the cellular localization of m6A proteins inside tumor cells has been little studied so far. Interestingly, recent evidence indicates that m6A methyltransferases are not always confined to the nucleus, suggesting that epitranscriptomic factors may also have multiple oncogenic roles beyond m6A that still represent an unexplored field. To date novel epigenetic drugs targeting m6A modifiers, such as METTL3 inhibitors, are entering into clinical trials, therefore, the study of the potential onco-properties of m6A effectors beyond m6A is required. Here we will provide an overview of methylation-independent functions of the m6A players in cancer, describing the molecular mechanisms involved and the future implications for therapeutics.

Keywords: cancer; epitranscriptomics; independent; m6A; mislocalization.

PubMed Disclaimer

References

REFERENCES

    1. Boccaletto P, Machnicka MA, Purta E, et al. MODOMICS: a database of RNA modification pathways. 2017 update. Nucleic Acids Res. 2018;46(D1):D303‐D307.
    1. Orsolic I, Carrier A, Esteller M. Genetic and epigenetic defects of the RNA modification machinery in cancer. Trends Genet. 2023;39(1):74‐88.
    1. Deng X, Qing Y, Horne D, Huang H, Chen J. The roles and implications of RNA m(6)A modification in cancer. Nat Rev Clin Oncol. 2023;20(8):507‐526.
    1. Sendinc E, Shi Y. RNA m6A methylation across the transcriptome. Mol Cell. 2023;83(3):428‐441.
    1. Meyer KD. How m(6)A makes its mark. Nat Rev Mol Cell Biol. 2022;23(8):519.

LinkOut - more resources